Objective Ceramides are associated with coronary plaque vulnerability. We aim to investigate the potential diagnostic value of ceramides for acute coronary syndrome (ACS) in Chinese patients with chest pain.
Design Prospective observational survey.
Setting Shanghai, China, 2016–2017.
Participants A total of 2773 patients with chest pain from four hospitals in Shanghai, China, between August 2016 and October 2017.
Main outcome measures Performance of metabolites model in detection of ACS cases including ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI) and unstable angina.
Results Plasma levels of 12 ceramide molecules and corresponding ratios were compared between patients diagnosed with ACS and those without. Cer(d18:1/24:1(15Z))/Cer(d18:1/24:0) ratio, Cer(d18:1/14:0) and Cer(d18:1/22:0) were independent predictors of ACS after adjustment of traditional risk factors and high-sensitivecardiac troponin T. Receiver operating characteristic curve analysis showed a significant improvement in detecting ACS in the multivariable model with ceramides compared with that without (0.865 (0.840 to 0.889) vs 0.808 (0.776 to 0.841), p<0.001).
Conclusion Distinct plasma ceramides are independent diagnostic predictors of ACS among patients with chest pain. Ceramides together with high-sensitive troponin and traditional factors showed great potential in identifying ACS among patients with chest pain.
- cardiac epidemiology
- lipid disorders
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
KY, YW and DX contributed equally.
Contributors JG, KY, YW and DX contributed to study concept and design. KY, XL, CS, WH, ZW, RW, XT, AS, YZ and JQ contributed to recruitment of patients and acquisition of samples. YW, GW, XG and XC contributed to analysis and interpretation of data. GW and YW drafted the first version of the manuscript. All authors contributed to critical revision of the manuscript and approval of final version.
Funding This work was supported by National Key Research and Development Programme (No. 2016YFC1301200) and National Natural Science Foundation of China (No. 81470386).
Competing interests Q-life lab holds patents for the diagnostic use of ceramides for cardiovascular risk determination in China. WG, GX and CX work for Q-life and GX and CX are also shareholders.
Ethics approval This study was approved by the Ethics Committee of Zhongshan Hospital, the Ethics Committee of Tongji Hospital, the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital and the Ethics Committee of Minhang Hospital.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Data are available with the corresponding author and will be available on request.
Patient consent for publication Obtained.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.